Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive management vs standard care in early psoriatic arthritis
2007-004757-28Phase 4Completed
- Sponsor
- University of Leeds
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of methotrexate and 5-aminosalicylic acid + sulphasalazine in psoriatic arthritis (PsA) (2 arms), sponsored by University of Leeds. Primary endpoint: ACR20 response at 48 weeks. Started Mar 2008; status: completed.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazine
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2007-004757-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004757-28.